Orser Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
+$582K |
| 2 |
Zoetis
ZTS
|
+$360K |
| 3 |
Amazon
AMZN
|
+$115K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Air Products & Chemicals
APD
|
+$2.37M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$2.33M |
| 3 |
Zimmer Biomet
ZBH
|
+$2.21M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$1.54M |
| 5 |
Chevron
CVX
|
+$1.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.27% |
| 2 | Consumer Discretionary | 9.66% |
| 3 | Financials | 7.94% |
| 4 | Consumer Staples | 7.69% |
| 5 | Healthcare | 7.65% |
Similar funds
Orser Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Orser Capital Management held 52 positions worth $91.7M, down 9.3% from $101M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Orser Capital Management withdrew a net $19.3M in Q4 2023, closing 10 positions and reducing 32 holdings. Its most notable exit was Air Products & Chemicals, an estimated $2.37M position sold in full.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Orser Capital Management added an estimated $582K to iShares MSCI Intl Quality Factor ETF.
- Orser Capital Management added most to iShares MSCI Intl Quality Factor ETF in Q4 2023, an estimated $582K increase.
- Orser Capital Management's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $2.33M.
- Orser Capital Management fully exited Air Products & Chemicals in Q4 2023, selling an estimated $2.37M.
- Orser Capital Management's ten largest holdings make up 57% of its $91.7M portfolio in Q4 2023.
- Orser Capital Management opened 0 new positions and closed 10 in Q4 2023.
- Orser Capital Management's portfolio value fell 9.3% quarter-over-quarter to $91.7M.
Based on Orser Capital Management's 13F filing for Q4 2023, filed 9 Jan 2024.